Literature DB >> 30664707

FcγRIII stimulation breaks the tolerance of human nasal epithelial cells to bacteria through cross-talk with TLR4.

K Golebski1,2, W Hoepel1,3, C M van Drunen2, J den Dunnen4,5, D van Egmond2, E J de Groot2, G D Amatngalim6,7, J M Beekman6,7, W J Fokkens2.   

Abstract

The nasal cavity displays immune tolerance to commensal bacteria under homeostatic conditions, which is rapidly converted to a pro-inflammatory response upon infection. Yet, the factors that control this conversion are still largely unknown. Here, we provide evidence that Fc gamma receptor III (FcγRIII) stimulation breaks immune tolerance to bacteria in the human nasal cavity through activation of nasal epithelial cells, which are the first line of defense against invading microbes. While under steady-state conditions human nasal epithelial cells were completely non-responsive to Gram-negative bacteria P. aeruginosa or TLR4 ligand LPS, IgG opsonization of bacteria, as occurs upon infection, strongly induced production of pro-inflammatory agents such as IL-6 and IL-8. This breaking of tolerance to bacteria was completely dependent on FcγRIII, which amplified cytokine gene transcription through cross-talk with TLR4. In addition, we identified that epithelial cells from patients suffering from chronic rhinosinusitis with nasal polyps do not display LPS tolerance, thereby providing an explanation for the disturbed host defense responses of these patients. Taken together, these data are the first to identify FcγR expression on nasal epithelial cells, as well as to identify its important role in controlling the balance between tolerance and inflammation in the nasal cavity.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30664707     DOI: 10.1038/s41385-018-0129-x

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  4 in total

1.  Immunoglobulins in nasal secretions of healthy humans: structural integrity of secretory immunoglobulin A1 (IgA1) and occurrence of neutralizing antibodies to IgA1 proteases of nasal bacteria.

Authors:  L Kirkeby; T T Rasmussen; J Reinholdt; M Kilian
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

2.  Serum immunoglobulin levels in healthy children and adults.

Authors:  J W Stoop; B J Zegers; P C Sander; R E Ballieux
Journal:  Clin Exp Immunol       Date:  1969-01       Impact factor: 4.330

3.  European Position Paper on Rhinosinusitis and Nasal Polyps 2012.

Authors:  Wytske J Fokkens; Valerie J Lund; Joachim Mullol; Claus Bachert; Isam Alobid; Fuad Baroody; Noam Cohen; Anders Cervin; Richard Douglas; Philippe Gevaert; Christos Georgalas; Herman Goossens; Richard Harvey; Peter Hellings; Claire Hopkins; Nick Jones; Guy Joos; Livije Kalogjera; Bob Kern; Marek Kowalski; David Price; Herbert Riechelmann; Rodney Schlosser; Brent Senior; Mike Thomas; Elina Toskala; Richard Voegels; De Yun Wang; Peter John Wormald
Journal:  Rhinol Suppl       Date:  2012-03

4.  Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum.

Authors:  D K Wagner; M L Clements; C B Reimer; M Snyder; D L Nelson; B R Murphy
Journal:  J Clin Microbiol       Date:  1987-03       Impact factor: 5.948

  4 in total
  8 in total

1.  The Importance of Glycosylation in COVID-19 Infection.

Authors:  Tea Petrović; Gordan Lauc; Irena Trbojević-Akmačić
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 3.650

2.  mTOR-driven glycolysis governs induction of innate immune responses by bronchial epithelial cells exposed to the bacterial component flagellin.

Authors:  I Ramirez-Moral; X Yu; J M Butler; M van Weeghel; N A Otto; B Lima Ferreira; L Van Maele; J C Sirard; A F de Vos; M D de Jong; R H Houtkooper; T van der Poll
Journal:  Mucosal Immunol       Date:  2021-02-04       Impact factor: 7.313

3.  High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages.

Authors:  Willianne Hoepel; Hung-Jen Chen; Chiara E Geyer; Sona Allahverdiyeva; Xue D Manz; Steven W de Taeye; Jurjan Aman; Lynn Mes; Maurice Steenhuis; Guillermo R Griffith; Peter I Bonta; Philip J M Brouwer; Tom G Caniels; Karlijn van der Straten; Korneliusz Golebski; René E Jonkers; Mads D Larsen; Federica Linty; Jan Nouta; Cindy P A A van Roomen; Frank E H P van Baarle; Cornelis M van Drunen; Gertjan Wolbink; Alexander P J Vlaar; Godelieve J de Bree; Rogier W Sanders; Lisa Willemsen; Annette E Neele; Diederik van de Beek; Theo Rispens; Manfred Wuhrer; Harm Jan Bogaard; Marit J van Gils; Gestur Vidarsson; Menno de Winther; Jeroen den Dunnen
Journal:  Sci Transl Med       Date:  2021-05-11       Impact factor: 17.956

Review 4.  Leveraging Antibody, B Cell and Fc Receptor Interactions to Understand Heterogeneous Immune Responses in Tuberculosis.

Authors:  Stephen M Carpenter; Lenette L Lu
Journal:  Front Immunol       Date:  2022-03-17       Impact factor: 7.561

Review 5.  The Role of IgA in Chronic Upper Airway Disease: Friend or Foe?

Authors:  Alba Sánchez Montalvo; Sophie Gohy; Philippe Rombaux; Charles Pilette; Valérie Hox
Journal:  Front Allergy       Date:  2022-03-09

Review 6.  Coronaviral Infection and Interferon Response: The Virus-Host Arms Race and COVID-19.

Authors:  Qi Liu; Sensen Chi; Kostyantyn Dmytruk; Olena Dmytruk; Shuai Tan
Journal:  Viruses       Date:  2022-06-21       Impact factor: 5.818

Review 7.  Physiological and Pathological Inflammation Induced by Antibodies and Pentraxins.

Authors:  Chiara Elisabeth Geyer; Lynn Mes; Melissa Newling; Jeroen den Dunnen; Willianne Hoepel
Journal:  Cells       Date:  2021-05-12       Impact factor: 6.600

Review 8.  Predicting Success of Allergen-Specific Immunotherapy.

Authors:  Ulrich M Zissler; Carsten B Schmidt-Weber
Journal:  Front Immunol       Date:  2020-08-25       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.